RxDoctor Payments Data

Michael Barmach, MD

Family Medicine · Doylestown, PANPI 1457475584

Payments from drug & device makers

$2,852in general payments, 2019–2025

Across 170 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$459
  • Amgen$394
  • AbbVie$381
  • Novo Nordisk$372
  • Lilly USA, LLC$279
  • Pfizer$161
  • plus $807 from 18 others

What the payments were for

  • Food & beverage$2,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,852 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$72,922
Medicare patients
240
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin117$113,899
OzempicSemaglutide52$58,014
JanuviaSitagliptin Phosphate37$37,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$30,041
FarxigaDapagliflozin Propanediol13$16,759
MyrbetriqMirabegron20$9,918
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,068
Cyclosporine12$6,709
VascepaIcosapent Ethyl12$5,632
Atorvastatin Calcium378$4,316
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,117
SynthroidLevothyroxine Sodium28$2,463
Metformin Hcl142$1,593
Rosuvastatin Calcium86$1,387
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$28$113,899117 claims
Novo NordiskOzempic$372$58,01452 claims
MerckJanuvia$103$37,54937 claims
GSKTrelegy Ellipta, Anoro Ellipta$152$37,11056 claims
AstraZenecaFarxiga$459$16,75913 claims
Astellas Pharma US IncMyrbetriq$47$9,91820 claims
AbbVieSynthroid$381$2,46328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →